Differential adherence to combination antiretroviral therapy is associated with virological failure with resistance
- 2 January 2008
- journal article
- clinical trial
- Published by Wolters Kluwer Health in AIDS
- Vol. 22 (1) , 75-82
- https://doi.org/10.1097/qad.0b013e3282f366ff
Abstract
Objectives: To investigate the occurrence of differential adherence to components of combination antiretroviral therapy and assess its predictors and association with virological failure and antiretroviral medication resistance. Design: A secondary analysis of prospective clinical trial data. Methods: The Flexible Initial Retrovirus Suppressive Therapies study (Community Programs for Clinical Research on AIDS 058) was a randomized trial comparing non-nucleoside reverse transcriptase inhibitor (NNRTI) versus protease inhibitor (PI) versus NNRTI plus PI-based (three-class) antiretroviral therapy in treatment-naive HIV-1-infected individuals. Adherence was assessed at months 1 and 4, and then every 4 months. Differential adherence , defined as any difference in self-reported level of adherence to individual antiretroviral medications at the same timepoint, was evaluated as a binary time-updated variable in multivariate Cox regression analyses of time to initial virological failure (HIV-RNA > 1000 copies/ml) and initial virological failure with genotypic antiretroviral resistance. Results: Differential adherence was reported at least once by 403 of 1379 participants (29%), over 60 months median follow-up. Differential adherence was more commonly reported by participants randomly assigned to the three-class strategy (35%) than the NNRTI (28%) or PI (25%) strategies (P = 0.005), but was not associated with demographic or baseline disease-specific factors. Of those reporting differential adherence , 146 (36%) reported it before initial virological failure. These participants had an increased risk of initial virological failure and initial virological failure with antiretroviral resistance compared with participants without differential adherence before initial virological failure. Conclusion: Differential adherence was commonly reported and was associated with an increased risk of initial virological failure and initial virological failure with antiretroviral resistance.Keywords
This publication has 26 references indexed in Scilit:
- A randomized comparison of two instruments for measuring self-reported antiretroviral adherenceAIDS Care, 2008
- Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapyAIDS, 2007
- Prevalence of Antiretroviral Drug Resistance Mutations in Chronically HIV-Infected, Treatment-Naive Patients: Implications for Routine Resistance Screening before Initiation of Antiretroviral TherapyClinical Infectious Diseases, 2005
- The Consistency of Adherence to Antiretroviral Therapy Predicts Biologic Outcomes for Human Immunodeficiency Virus–Infected Persons in Clinical TrialsClinical Infectious Diseases, 2002
- Factors Affecting Adherence to Antiretroviral TherapyClinical Infectious Diseases, 2000
- Predictors of Self-Reported Adherence and Plasma HIV Concentrations in Patients on Multidrug Antiretroviral RegimensJAIDS Journal of Acquired Immune Deficiency Syndromes, 2000
- Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease.Health Psychology, 2000
- Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1998
- Zidovudine Alone or in Combination with Didanosine or Zalcitabine in HIV-Infected Patients with the Acquired Immunodeficiency Syndrome or Fewer Than 200 CD4 Cells per Cubic MillimeterNew England Journal of Medicine, 1996
- In Vivo Resistance to a Human Immunodeficiency Virus Type 1 Proteinase Inhibitor: Mutations, Kinetics, and FrequenciesThe Journal of Infectious Diseases, 1996